These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 26747)
1. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? MacKay D J Pharm Pharmacol; 1978 May; 30(5):312-3. PubMed ID: 26747 [No Abstract] [Full Text] [Related]
2. pA2 and receptor differentiation: a statistical analysis of competitive antagonism. Tallarida RJ; Cowan A; Adler MW Life Sci; 1979 Aug; 25(8):637-54. PubMed ID: 388133 [No Abstract] [Full Text] [Related]
4. Quantification of receptor interactions using binding methods. Lazareno S J Recept Signal Transduct Res; 2001; 21(2-3):139-65. PubMed ID: 11757681 [No Abstract] [Full Text] [Related]
5. Experimental procedure for estimating the dissociation constant of noncompetitive interactants. Part I. Orsetti M Boll Soc Ital Biol Sper; 1986 Jan; 62(1):51-7. PubMed ID: 3718726 [No Abstract] [Full Text] [Related]
6. [Experimental allergy as a model of pharmacological activity]. Alonso de Florida F Bol Estud Med Biol; 1983; 32(7-8 Suppl 1):53-65. PubMed ID: 6100436 [No Abstract] [Full Text] [Related]
7. The use of competitive ligand binding results in QSAR studies. Gómez-Jeria JS Farmaco Sci; 1985 May; 40(5):299-302. PubMed ID: 4007152 [TBL] [Abstract][Full Text] [Related]
8. Theoretical treatment of events between the drug-receptor association and the effect. Gero A J Theor Biol; 1983 Sep; 104(2):249-59. PubMed ID: 6645557 [TBL] [Abstract][Full Text] [Related]
10. The use of drug-receptor affinity measures in the differentiation of receptors. Tallarida RJ Fed Proc; 1982 May; 41(7):2323-7. PubMed ID: 6122613 [TBL] [Abstract][Full Text] [Related]
12. On the estimation of receptor occlusion by irreversible competitive pharmacological antagonists. Waud DR Biochem Pharmacol; 1968 May; 17(5):649-53. PubMed ID: 5649887 [No Abstract] [Full Text] [Related]
13. [Receptor occupation theory and its parameter estimates (author's transl)]. Xu DZ Sheng Li Ke Xue Jin Zhan; 1981 Oct; 12(4):318-24. PubMed ID: 7344074 [No Abstract] [Full Text] [Related]
14. [Receptors; from idea to reality]. Ariëns EJ Ned Tijdschr Geneeskd; 1983 Jul; 127(28):1235-8. PubMed ID: 6310420 [No Abstract] [Full Text] [Related]
15. How we describe competitive antagonists: three questions of usage. Jenkinson DH Trends Pharmacol Sci; 1991 Feb; 12(2):53-4. PubMed ID: 2024288 [TBL] [Abstract][Full Text] [Related]
16. The model of functional interaction. I. Development and first check of a new model of functional synergism and antagonism. van den Brink FG Eur J Pharmacol; 1973 Jun; 22(3):270-8. PubMed ID: 4147331 [No Abstract] [Full Text] [Related]
17. Steady state variables in the guarded receptor hypothesis. Schanne OF Am J Physiol; 1991 Dec; 261(6 Pt 2):H2098-100. PubMed ID: 1721503 [No Abstract] [Full Text] [Related]
18. Clinically important drug interactions. Prescott LF Drugs; 1973; 5(3):161-86. PubMed ID: 4576570 [No Abstract] [Full Text] [Related]
19. Estimating pA2 values for different designs. Ott L; Weiner D; Cheng H; Woodward J J Pharmacol Methods; 1981 Jan; 5(1):75-92. PubMed ID: 7265988 [TBL] [Abstract][Full Text] [Related]
20. The classification of drugs and drug receptors in isolated tissues. Kenakin TP Pharmacol Rev; 1984 Sep; 36(3):165-222. PubMed ID: 6093156 [No Abstract] [Full Text] [Related] [Next] [New Search]